specific antigen detected by monoclonal antibody (MAb) 2 33.1.3 It was postulated that the 33.1 antigen is a non-DR but Ia-like molecule encoded or regulated by a gene(s) linked to those responsible for the expression of the human analogue (DC) of the murine I-A region. We now present further evidence to support this assignment from analyses of DR homozygous typing cells and DR "null" mutant cell lines, and from partial N-terminal-radiolabeled amino acid sequence analyses. These results suggest that the 33.1 antigen is closely related to previously described human I-A antigens (DS and DC).
721.45.1 was irradiated and immunoselected with MAb L243 (a-HLA-DR monomorphic; 22, 23) to isolate several DR null mutant cell lines (49) . They are designated DR null because they neither bind MAb L243 in an enzyme-linked immunosorbent assay (ELISA) nor are they killed by anti-HLA-DR-typing alloantisera in complement-dependent cytotoxicity tests (24) . Some of the DR null mutant cell lines continued to express DC1/MB1, while other did not. All of the DR null mutant cell lines express SB2 (22) .
Surface Immunofluorescence (slF) and Flow Cytometry (FCM).
The methods used have been described in a previous paper? Briefly, cells were washed in phosphate-buffered saline (PBS) with 0.02% sodium azide. For both microscopic sIF and FCM, 106 cells were incubated with saturating amounts of MAb, washed, and stained with fluorescein-or rhodamine-conjugated goat anti-mouse antiserum (IgG fraction; Cappel Laboratories Inc., Cochranville, PA). A Leitz Ortholux epifluorescence microscope (E. Leitz, Inc., Rockleigh, N J) or a fluorescence-activated cell sorter (FACS II; B-D FACS Systems, Sunnyvale, CA) was used to observe and record sIF, In a separate series of experiments, MAb 61D2, 33.1, and I-2 were conjugated with fluorescein or rhodamine using conventional methods. These reagents were used to evaluate capping of the respective antigens recognized by these reagents. For co-capping experiments, BLCL cells were stained sequentially with fluoresceinated MAb I-2 and rhodamine-conjugated MAb 33.1. After the cells had been incubated at 37°C for various amounts of time (10-60 min), the second MAb was added in PBS containing 0.02% sodium azide. Papain-treated cells were prepared by the method of Schwartz and Nathenson (25) and examined for sIF after 5-60 min of digestion. The anti-HLA framework MAb was used as a positive control. Tunicamycin-treated cells (26) were also examined.
ELISA.
Immunoassay plates (flat-bottomed) 96-weU, NUNC 4-39454) were pretreated by a 30-min incubation at room temperature (RT) with 50 #1 of poly-L-lysine solution (10 ug/ml in PBS; Sigma Chemical Co., St. Louis, MO). Cells harvested during exponential growth (105 per well in 100 #1) were centrifuged and fixed with 100 #i of 0.5% glutaraldehyde for 15 min at RT. The glutaraldehyde was removed by two washes with PBS and further inactivated by incubation for 30 rain at RT with 100 #l of 100 mM glycine in PBS containing 0.1% bovine serum albumin (BSA). Antibody binding to fixed cells was evaluated using a beta-galactosidase-conjngated F(ab')z sheep anti-mouse IgG (heavy and light) (9502SA; Bethesda Research Laboratories, Rockville, MD). The ELISA was conducted as previously described (27) except that p-nitrophenyl-/~-gaiactopyranoside was used as the substrate. The reaction was quenched with 0.5 M calcium carbonate solution and read on an automated ELISA reader (Flow Laboratories, McLean, VA) at 405 nm wavelength. The binding of MAb 33.1 was titrated on the HLA-hapioid mutant cell line 721.45.1 with HLA genotype A2-B5-DR1-MBI-Dwl-SB2. Half-maximum binding was observed at an antibody concentration of ~ 1:8,000 dilution of AF. Results are given as the mean OD × 1,000 for duplicate samples.
Isolation of Radiolabeled 33.1 Antigen. Various BLCL cells (1-5 × 108) were radiolabeled with [3H]phenylalanine ([3H]Phe) (1-5 mCi) using methods previously described (28) . Cells were radiolabeled for 8-16 h in mid-log phase; at the termination of labeling, viability was 285%. Incubation periods for the incorporation of the [s~S]methionine were 8-10 h. In some experiments, tunicamycin (8-10 #g/ml) was added to the cells being radiolabeled (26) . Radiolabeled cells (40-60% incorporation) were lysed in 0.25% Nonidet P-40, 10 mM Tris, 0.15 M NaCI, pH 8.0. The detergent lysate was centrifuged at 100,000 g for 60 min and applied directly to an immunoadsorbent column containing either MAb 33.1, IVG1, or I-2. Specifically bound material was eluted with 0.5% diethylamine and neutralized with 2 M Tris, pH 8.0. The eluted material was concentrated and dialyzed by ultrafiltration using a PM10 membrane (Amicon Corp., Danvers, MA). Samples were analyzed on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli (29) . Analytical slab gels were fixed in 50% trichloroacetic acid, dried, and autoradiographed using Kodak X-Omat AR film with an intensifying screen (30) . Samples for protein sequence analysis were isolated by using preparative SDS-PAGE with a 10-15% acrylamide gradient in 20-cm tubes. The gels were extruded, frozen at -20°C, and sliced in 2-mm sections. The sections were incubated overnight at 40-50°C in 0.001% SDS to elute the peptide chains. After counting samples of these fractions to determine the positions of the chains, fractions were pooled, centrifuged to remove acrylamide debris, and lyophilized to dryness. Dried samples were taken up in 0.5-1.0 ml of 0.001% SDS for amino acid sequence analysis.
Amino Acid Sequence Determination. The method used has been previously described (28) . Briefly, the sequences of the isolated a and 3 chains were determined on an automated sequencer (model 890C; Beckman Instruments, Inc., Fullerton, CA). Butyl chloride extracts were collected and evaporated to dryness under N2; scintillation fluid was added (Biofluor; New England Nuclear, Boston, MA) and radioactivity measured (Beckman LC 9000; Beckman Instruments, Inc.).
Sequential Immunoadsorption Affinity Column Chromatography. A [3H]
Phe-labeled HOM-2 lysate was sequentially passed through 33.1-Sepharose and IVG 1-Sepharose immunoadsorption columns. The lysates were cycled overnight in the cold on each column. The columns were washed first with starting buffer and then with 2% sodium deoxycholate until the radioactivity decreased to background level. The specifically bound material was eluted with 3 M NH4SCN and immediately desalted on Sephadex G-25 that was connected directly to the immunoadsorbent column, a and/3 chains were isolated as described above.
Results

slF.
Panel studies were undertaken to evaluate the association between 33.1 and DR antigens. A representative survey of cells tested by FCM and microscopic slF with MAb 33.1 is summarized in Table I . EBV BLCL derived from individuals homozygous for DR 1, 2, 4, 5, and w6 are positive while most DR3/3 and DR7/7 cells are unreactive. DRw8, DRw9, or DRwl0 homozygous cells were not available to us, but cells heterozygous for DRw8 (7/w8) or DRw9 (7/w9) are positive. Microscopic slF consistently revealed that ->95% of the cells of a given (47) . ! M 17B is EBV BLCL derived from an individual with an HLA-A3 variant (48) .
positive cell line expressed the 33.1 antigen. This finding was confirmed by FCM (data not shown). The presence of 33.1 on EBV-transformed cells may be an autologous marker of B cell activation as previously suggested (14) .
In an attempt to demonstrate the nonidentity of the 33.1 antigen with DR antigens, dual fluorescence studies were undertaken. Dual fluorescent experiments using MAb 33.1 and MAb I-2 (a-HLA-DR, monomorphic) showed that induction of surface patching by MAb 33.1 did not affect the surface distribution of DR as detected by MAb I-2. Also, there was no decrease in sIF of MAb 33. from that of DR (which is lacking in all the DR null cell lines) and of SB (which is retained in all the DR null cell lines).
Comparative SDS-PAGE A~alysis of the 33.1 Antigen. To demonstrate that the 33. I antigen is different from HLA-DR antigens, HOM-2 lysates were sequentially passed through 33.1-Sepharose and IVG1-Sepharose immunoadsorption columns. The sequentially immunoadsorbed 33.1 antigen and IVG1 antigen differ according to their electrophoretic mobility of SDS-PAGE (Fig. 2) . There are multiple bands on the slab gel for both ~ and fl chains of these antigens, presumably due to differential glycosylation or heterogeneity of molecules within the Ia family. Under reducing conditions, the 33.1 antigen has a 34,000 mol wt (34 K) a chain that is substantially smaller than the a chain (35 K and 37 K) of the IVG1 (DR) antigen. The two reduced 3 chain bands (27.5 K and 29 K) of 33.1 have molecular weights similar to the 3 chain of IVG1 antigen. Under nonreducing conditions, the apparent molecular weight of the 33.1 antigen oe chain (32.5 K) is still less than that of the IVG1 antigen a chain (34 K and 36 K); the apparent molecular weight of the nonreduced 3 chain of the 33.1 antigen (22 K) is less than the major band of IVG1 antigen 3 chain (24 K). These observations not only demonstrate the nonidentity of s-DR (IVG1) and 33.1 chains, but also suggest the nonidentity of their respective/3 chains.
The 33.1 antigen could be isolated from cell lysates bound to lectin columns, indicating the presence of a carbohydrate side chain. A decrease in the apparent molecular weight of the 33.1 antigen after exposure of cells to tunicamycin is also consistent with this interpretation (Fig. 3) . Although tunicamycin treatment only partially inhibited glycosylation in this experiment, the nonglycosylated /3 chain (21 K) is 3,000 tool wt smaller than the glycosylated 3 chain (Fig. 3) . Due to the interference of glycosylated/3 chain, the nonglycosylated 0t chain is not well identified.
Amino Acid Sequence Determination of 33.1 a (or Heavy) and 3 (or Ligh 0 Chains. The ascending portion of the 0~ chain peak and the descending portion of the/3 chain peak eluted from SDS-PAGE gels were pooled separately so as to (Table II) , its 33.1 a chain sequence is the same as that obtained for the o t h e r 
Discussion
This report describes the isolation and initial characterization of a new human B lymphocyte-specific antigen, 33.1. This antigen can be detected and isolated using murine MAb 33.1, prepared by immunization of mice with a human D/ DR2 lymphoblastoid cell line. The data presented in this report show that 33.1 is a human class II major histocompatibility complex (MHC) antigen that is clearly not DR. The antigen is homologous to the previously described non-DR antigens DS and DC but can be distinguished from them by both structural and cellular distribution data (11, 13).
The class II nature of 33.1 was suggested by earlier studies 3 indicating that the antigen is present on B cells and not on T cells, and SDS-PAGE analysis demonstrated that 33.1 consists of two noncovalently associated chains with molecular weights appropriate for class II antigens. In addition, intrachain disulfide bonds were shown to be present. The present report shows, in addition, that 33.1 is a glycoprotein and that it exhibits, on the cell surface, the expected resistance to papain digestion.
Two kinds of evidence suggest that the 33.1 antigen maps to or is genetically controlled in the D/DR region of the MHC. First, the antigen is absent on most DR3 and DR7 homozygous cell lines. This association was confirmed by ELISA. MAb 33.1 binds to BLCL 721 and to 721.45.1 from which the DR3 expression has been deleted but fails to bind significantly to mutants that retain DR3 (721.127) after loss of the DR1 haplotype (Table I) . Second, the expression of the 33.1 antigen was lost only on those DR null mutants lacking DC1/MB1 reactivity. This is strong evidence that genes controlling the expression of DC1 and 33.1 are linked closely enough to be deleted together. Attempts are being made to isolate mutants that lose expression of either DC 1 or 33.1 but not both.
Numerous lines of evidence show that 33.1 is not DR. MAb directed against DR can be used to exhaustively deplete cell lysates of DR antigens without affecting the level of 33.1 and vice versa. Capping of 33.1 on the cell surface does not lead to capping of DR antigens. When DR and 33.1 are isolated from the same cell line, the ~ and /3 chains of 33.1 can be shown to be of lower molecular weight than the corresponding DR chains. Although some investigators (5) have been unable to detect molecular weight differences between DR and non-DR but Ia-like antigens, this does not appear to be the case for 33.1 and DR. Furthermore, partial N-terminal sequence analysis conclusively demonstrates that major differences exist between 33.1 and DR in both chains.
While 33.1 is clearly a non-DR, class II antigen, the relationship between 33.1 and previously described non-DR antigens is more difficult to determine (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) . Two distinct non-DR loci, SB and DC, are universally recognized (2, 10, 13, 31, 40) . It is possible to distinguish 33.1 and SB quite easily by amino acid sequence analysis and by mapping using a panel of DR null mutant cell lines. However, the structural and mutant cell pane] data demonstrate that 33.1 is a member of the DC family of molecules.
The DC family appears to include the human homologues of the mouse I-A antigens. The diversity that exists within this family is currently an active area of research. Studies at the nucleic acid level sugest a level of complexity sufficient to encompass a number of related antigens (41) . Evidence has been presented that there are at least two DC-like ~ chain genes (10, 41, 42) and several DC-like /3 chain genes (8, (41) (42) (43) . It is unknown whether all of these genes are expressed at the protein level and whether any restrictions exist with respect to association between the gene products of the various a and/3 chains either within the DC family or more widely among other class II antigens.
The two members of the DC family that have been described in sufficient detail to permit comparisons with 33.1 are DC1 and DS. While there are similarities among the three antigens, there are differences both in structural features and in the pattern of expression. The limited protein sequence data available reveal some differences. The amino acid N-terminal sequences of the 33.1 and DC1 o~ chains are indistinguishable, with Phe at positions 18 and 29.
Although inconclusive, no Phe was found at residue 18 in the DS ot chain. The /3 chain of DC1 has been reported to be blocked (10) . The two 33.1 /3 chains from DR2/DW2 homozygous cell lines contain Phe at positions 7, 9, 11, and 17, but DS from a DR2/DW2 cell line (GM3107) lacks the Phe at position 9 even though Phe is present at position 7 and 11. Furthermore, the 33.1 13 chain isolated from GM3107 (PGF) does contain Phe at position 9, further suggesting that 33.1 and DS may not be identical when isolated from the same cell line. In a similar investigation using five radiolabeled amino acids and murine MAb IVD12 (anti-MB3), Giles et al. (44) have noted structural variations between IVD12 and DS/3 chains. They have tentatively attributed this variation to the existence of polymorphic alleles. The 33.1 /3 chain sequences do exhibit polymorphism at Phe positions. The existence of a DR null, DC null, 33.1-positive mutant cell line would provide direct evidence that 33.1 and DC1 are different.
In addition to the amino acid sequence differences between 33.1 and other human I-A antigens (DS, DC), the patterns of tissue distribution vary considerably for these antigens. MAb 33.1 recognizes a B cell-specific antigen. Expression of this antigen is restricted to BLCL, activated and neoplastic B cells (CLL lymphocytes included), and unstimulated B lymphocytes of blood, tonsil, lymph nodes, and spleen? In contrast, Gonwa et al. (45) , using a rabbit anti-marmoset I-A antiserum, have shown that the majority of human blood monocytes express the DS antigen. There is a striking similarity in the tissue distribution of the 33.1 and IVD12 antigens on a small population of blood monocytes and on CLL lymphocytes (44). Shackelford et al. (13) have used MAb Genox 3.53 to isolate and characterize DC1. As detected by Genox 3.53, DC1 is present on BLCL and peripheral blood B cells but is absent on blood T iymphocytes and Molt 4 cells. Lung macrophages were stated to be positive (46) . While 33.1, DC, DS, and IVD12 are very similar with respect to their a chain sequences, they do not appear to be identical in/3 chain sequences. More extensive protein sequence data or transfection experiments using cloned a and 13 chains genes will be required to relate the various class II antigens to the various a and /3 chain genes that have been detected and partially characterized. Direct comparison of the various antigens, using the same set of reagents and the same cell lines for study, may ultimately be necessary to resolve these questions. The distinctive tissue distributions, particularly the absence of 33.1 on monocytes and PHA blasts and, in contrast, the presence of DC1 on monocytes and PHA blasts, suggest that these similar antigens may be very different in their functional roles in cell-cell recognition (45) . The availability of reagents such as MAb 33.1 should, in conjunction with studies at the nucleic acid level, facilitate the functional and molecular dissection of the human Ia antigen system as it relates to immune regulation and associated disease states.
Summary
The polymorphic human B cell-specific antigen, 33.1, detected by a murine monoclonal antibody, was compared by genetics and structural analysis with known human Ia antigens from a panel of DR homozygous Epstein-Barr virus-transformed B lymphoblastoid cell lines. Cells homozygous for DR 1, 2, 4, 5, and w6 were positive, while cells that are DR3,3 or DR7,7 usually failed to express this antigen. Mutant DR null, DC/MB-positive cells were 33.1 positive while DR null, DC/MB-negative cells failed to express this antigen, suggesting the segregation of 33.1 with the DC antigen. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis revealed that 33.1 a and 3 chains were of lower molecular weights than the DR ot and 3 chains isolated from the same cell line. Partial N-terminal amino acid sequence analyses were carried out for the heavy and light chains of the 33.1 antigen radiolabeled with [SH]phenylalanine. The results of these analyses, in conjunction with previous data on tissue distribution, indicate that the 33.1 antigen is a non-DR but Ia-like antigen closely related to the previously defined I-A homologues, DC and DS.
